GlassScriptPhysician profile
Sarah E Jakubowski
NPI 1013983154
$6,178.65
in general payments reported to CMS, 2019-2025
44 companies · $1,030 in 2025
The $1,030 reported for 2025 was more than what 81% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $954 · 2022: $1,071 · 2023: $1,647 · 2024: $1,476 · 2025: $1,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,153.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $813.67 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $771.52 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $554.72 | 2021-2025 | Evenity, Prolia, Otezla |
| Abbvie INC. | $519.55 | 2021-2025 | |
| Pfizer INC. | $509.09 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $360.88 | 2021-2024 | Jardiance, Tradjenta, Ofev |
| Phathom Pharmaceuticals, INC. | $319.04 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $174.78 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $165.10 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Xeris Pharmaceuticals, INC. | $146.61 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Abbott Laboratories | $133.11 | 2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $129.18 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $118.45 | 2022-2025 | Veozah, Myrbetriq |
| Vivus LLC | $111.52 | 2023-2025 | Qsymia |
| E.R. Squibb & Sons, L.L.C. | $109.41 | 2022-2025 | Eliquis |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Jakubowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.